echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Multinational giant China's cold mainland market is still a battle for strategists

    Multinational giant China's cold mainland market is still a battle for strategists

    • Last Update: 2015-08-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Bio Valley 2015-8-10 Chinese market has always been valued by multinational enterprises in the world, and bio pharmaceutical industry is one of the representatives The huge population base, relatively backward drug research and development level and so on all make the international biomedical giants who enter early obtain satisfactory returns However, just after the first half of 2015, financial reports from major biomedical giants showed that perhaps the Chinese Biomedical market is no longer the paradise they had imagined First, Novo Nordisk 's diabetes business is no longer thriving According to Novo Nordisk's second quarter results, the company's business growth in the second quarter of 2015 was only about 3%, which was almost unimaginable in the past Novo Nordisk officials attributed the huge drop to the slow transportation of dealers and the slowdown of China's diabetes market In addition, the Chinese government began to cut government spending and severely cracked down on the bribery of medical representatives to doctors On the other hand, China's local pharmaceutical companies have also set foot in the field of diabetes, which also makes this field, which was originally the only one of Novo Nordisk, become crowded Lilly's second quarter sales fell 16% Like Novo Nordisk, Chilo zuleueta, Lilly's head of emerging markets, agrees that competition from generic drugs has a big impact on the company Zulueta also said that in the future, companies may face more pressure from generic drugs However, Joe Jimenez, CEO of Novartis, believes that as China consciously controls the speed of economic development, the investment in the pharmaceutical industry in China has declined These are the important reasons why the company's business growth is not as good as before However, Joe Jimenez also pointed out that for Novartis, the Chinese market business still plays a very important role in driving the overall business growth of the company It's hard to ignore GlaxoSmithKline, the British pharmaceutical giant The poor market reaction and the fact that the company has just emerged from the whirlpool of bribery make the second quarter performance of the old company almost unsustainable Sales fell by as much as 16% in the second quarter In order to reverse this situation, GlaxoSmithKline finally chose the price for sales strategy, but whether it works is still unclear AstraZeneca, also from the UK, was the last to laugh AstraZeneca grew by 10% in the second quarter, the only multinational biopharmaceutical giant to achieve double-digit growth, according to Reuters This also led to AstraZeneca's sales growth of about 19% in the first half of 2015 At the same time, AstraZeneca officials said that despite some pressure, the company was confident of ensuring double-digit growth in the second half of the year Bio Valley editor once saw an analysis that the dividend period of multinational enterprises in China has ended And it seems reasonable for the biomedical industry However, Xiaobian believes that it is China's biomedical industry that should be more vigilant and reflective As the R & D capacity of Chinese Biomedical enterprises is still relatively weak, multinational enterprises will still maintain this advantage for a long time If the basic R & D capacity cannot be strengthened, it will be difficult for Chinese pharmaceutical enterprises to get rid of this passive situation On the other hand, with the process of China's aging and who's requirements for China's economic openness, China has always been a huge attraction to the major transnational biomedical giants, which also means that China will still be a place for their strategists in the next few years, so China's biomedical industry will also face pressure from transnational pharmaceutical enterprises for a long time.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.